Identification and validation of a non-genetically encoded vulnerability to XPO1 inhibition in malignant rhabdoid tumors - expanding patient-driven discovery beyond the Nof1.
L. J. Marks, D. Diolaiti, P. Mundi, E. S. Gaviria, A. R. Rainey, D. J. Yamashiro, L. Fazlollahi, H. Hosoi, Y. Katsumi, Y. Kuwahara, F. S. Dela Cruz, A. Califano, A. L. Kung
This study identifies XPO1 activation as a non-genetic vulnerability in malignant rhabdoid tumors using patient-driven discovery and validates selinexor as a potential therapeutic.
bioRxiv · Oct 2, 2021 · PreprintCancer Biology